RXRX 8-K 2026-10-15

RECURSION PHARMACEUTICALS, INC. (RXRX) 8-K dated 2026-10-15 — accession 0001601830-26-000128. This URL is the filing, not the RXRX hub.

RECURSION PHARMACEUTICALS, INC. (RXRX) is a biotechnology company listed on NASDAQ.

RXRX to acquire platform ($200M)

Cached items: 1.01, 2.02, 7.01, 8.01, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported RXRX revenue for 2025-12-31 was $74.7M. Net income was -$644.8M. Revenue was up 26.9% from 2024-12-31 to 2025-12-31. RXRX currently screens at market cap $1.75B.

Not investment advice. The RXRX SEC hub lists recent forms. The stock page is the research view.